腫瘤是嚴(yán)重危害人體健康的疾病之一，胃腸腫瘤是我國(guó)人口中消化系腫瘤的多發(fā)病種，而針對(duì)其進(jìn)行放療、化療治療的同時(shí)對(duì)正常細(xì)胞毒性不容忽視。中藥多糖抗腫瘤的同時(shí)，能提高人體免疫功能，且對(duì)正常細(xì)胞無(wú)傷害，使其成為抗腫瘤研究的熱點(diǎn)。對(duì)中藥多糖體外抑制人胃癌細(xì)胞系MGC-803、SGC-7901，人結(jié)直腸腺癌細(xì)胞LoVo、HCT-116、HT-29的增殖和促凋亡作用及相關(guān)作用機(jī)制進(jìn)行綜述，旨在為中藥多糖的抗胃腸腫瘤的臨床研究提供依據(jù)。

Tumor is a seriously disease that endanger human health. Gastrointestinal cancer is one of the most prevalent types of digestive system cancers among the Chinese population. While radiotherapy and chemotherapy kill cancer cells, their toxicity to normal cells cannot be ignored. Hence, polysaccharides from Chinese materia medica (CMM) have been the focus of anti-tumor research, as they can improve functions of the immune system and do not harm to normal cells. In this review, we have analyzed the recent advances in the study of the effects of polysaccharides from CMM on human gastric cancer cell lines (MGC-803 and SGC-7901) and intestinal tumor cell lines (LoVo, HCT-116, and HT-29) in vitro. The purpose of this study is to provide a material basis for clinical research of polysaccharides from CMM.

國(guó)家自然科學(xué)基金項(xiàng)目（81273636）；天津市重大科技攻關(guān)項(xiàng)目（12ZCDZSY16800）